Exelixis Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Apr '26 Apr 3, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	833.42	782.57	521.27	207.77	182.28	231.06
Depreciation & Amortization	28.66	29.06	28.8	25.72	20.88	13.63
Stock-Based Compensation	116.1	112.98	93.84	106.35	107.57	119.82
Other Adjustments	29.31	150.86	69.52	7.47	64.68	75.3
Change in Receivables	-47.31	-21.4	-27.95	-22.62	66.85	-122.32
Changes in Inventories	8.91	12.23	5.45	-12.98	-11.68	-13.21
Changes in Accounts Payable	-76.55	-50.15	-21.89	50.11	23.36	55.09
Changes in Unearned Revenue	-	-	-	-	-	11.01
Changes in Other Operating Activities	-94.1	-131.87	30.93	-28.48	-91.32	30.42
Operating Cash Flow	924.68	884.27	699.97	333.32	362.61	400.8
Operating Cash Flow Growth	9.74%	26.33%	110.00%	-8.08%	-9.53%	91.79%
Capital Expenditures	-6.99	-8.43	-28.44	-40.47	-27.71	-54.23
Purchases of Intangible Assets	-12.52	-31.5	-37.75	-122.5	-110.75	-10
Purchases of Investments	-719.96	-632.5	-927.91	-902.47	-1,451	-1,357
Proceeds from Sale of Investments	989.07	1,023	877.31	1,038	1,065	1,379
Investing Cash Flow	249.61	350.44	-116.78	-26.96	-524.41	-42.88
Issuance of Common Stock	44.98	49.14	61.85	33.45	23.89	24.31
Repurchase of Common Stock	-1,177	-1,019	-690.66	-579.5	-23.3	-39.11
Net Common Stock Issued (Repurchased)	-1,132	-969.59	-628.81	-546.05	0.59	-14.8
Financing Cash Flow	-1,132	-969.59	-628.81	-546.05	0.59	-14.8
Net Cash Flow	42.4	265.11	-45.62	-239.68	-161.21	343.12
Free Cash Flow	917.69	875.84	671.54	292.86	334.91	346.58
Free Cash Flow Growth	4.78%	30.42%	129.31%	-12.56%	-3.37%	94.01%
FCF Margin	38.63%	37.75%	30.96%	16.00%	20.79%	24.15%
Free Cash Flow Per Share	3.44	3.11	2.27	0.91	1.03	1.08
Levered Free Cash Flow	693.35	633.4	536.13	201.66	95.8	273.78
Unlevered Free Cash Flow	638.08	576.01	477.23	131.77	70.24	267.9

SEC Filings: 10-K · 10-Q